OPKO Health, Inc.OPK announced the launch of its kidney drug Rayaldee (calcifediol). The company said it will begin shipping of the drug to distributors in the United States on Nov 29, 2016. Rayaldee extended release capsules were approved by the FDA in June this year for treating secondary hyperparathyroidism (SHPT) in patients above 18 years with stage III or IV chronic kidney disease (CKD). The product will be available nationwide at retail pharmacies from Nov 30.
Rayaldee was introduced to nephrologists at the American Society of Nephrology (ASN) Kidney Week Meeting held last week in Chicago. Rayaldee is the first product developed by OPKO Health. The product has side effects like anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. However, this launch is expected to immensely help patients with CKD.
OPKO Health is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA, Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK. Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 93.31% year to date for the company.
Arbutus’ loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika’s earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%. Share price has increased 13.42% year to date for the company.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.